English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

: Psoriasis is a chronic immune-mediated inflammatory disease. Human cathelicidin (hCAP18/LL37) has been elucidated recently as a modulator of inflammation in the affected skin. Vitamin D may induce expression of this antimicrobial peptide. Our trial aimed to study the circulating level of hCAP18/LL-37 and to explore its relationship with the severity of psoriasis. Material and Methods : 79 patients with moderate to severe psoriasis (PASI >10) were included in a retrospective analysis. Stored serum samples were used for assessment of 25-hydroxyvitamin D - 25(OH)D and to measure the circulating human cathelicidin (LL-37). Results : In a study group of 79 patients we assessed mean level of 25(OH)D of 30.25 nmol/l (95% CI 25.87 – 34.62 nmol/l). Mean circulating cathelicidin was 27.17 ng/ml (95% CI 21.52 – 32.83 ng/ml). Only 8.9% of patients had LL-37 level > 54 ng/ml. Although circulating LL-37 was lower in severe psoriasis than in moderate psoriasis (24.33 ng/ml vs. 31.14 ng/ml), the variation is nonsignificant. We further evaluated the association of LL-37 with both PASI score and 25(OH)D concentration in the subgroup of patients with vitamin D deficiency (n=39). It was interesting to find a significant correlation between the level of LL-37 and 25(OH)D (r=0.38, p=0.017) and inverse association between the level of LL-37 and PASI (r= -0.30, p=0.06). Conclusion : In this pilot trial we assessed low serum levels of cathelicidin antimicrobial peptide in the patients with psoriasis. LL-37 may be discussed as related to PASI and 25(OH)D in a subgroup of psoriatic patients with vitamin D deficiency.

Serum level of the human antimicrobial cathelicidin (hCAP18/LL-37) in patients with psoriasis vulgaris